Steen Dalby Kristensen

Author PubWeight™ 109.81‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 20.09
2 Universal definition of myocardial infarction. Circulation 2007 11.69
3 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013 9.54
4 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007 9.43
5 European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007 6.10
6 Concern Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009 3.14
7 European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007 2.70
8 Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J 2009 2.68
9 New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012 2.41
10 Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet 2013 2.39
11 Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet 2010 2.38
12 Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost 2014 2.29
13 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 2014 2.10
14 Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol 2010 1.92
15 Anticoagulants in heart disease: current status and perspectives. Eur Heart J 2007 1.73
16 Marine n-3 polyunsaturated fatty acids and coronary heart disease. Part I. Background, epidemiology, animal data, effects on risk factors and safety. Thromb Res 2005 1.62
17 Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus- and sirolimus-eluting stents (from the SORT OUT IV trial). Am J Cardiol 2012 1.59
18 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol 2014 1.59
19 [Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation]. G Ital Cardiol (Rome) 2009 1.52
20 Routine thrombectomy in percutaneous coronary intervention for acute ST-segment-elevation myocardial infarction: a randomized, controlled trial. Circulation 2006 1.49
21 Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013 1.36
22 A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010 1.24
23 Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011 1.23
24 Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation 2012 1.17
25 Letter by Grove and Kristensen regarding article, "Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction". Circ Cardiovasc Interv 2013 1.07
26 Long genuine coronary artery lesions treated with stiff tubular or flexible coiled stents. A randomized angiographic follow-up study. Scand Cardiovasc J 2002 1.07
27 General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013 0.99
28 Determinants and patterns of utilization of primary percutaneous coronary intervention across 12 European countries: 2003-2008. Int J Cardiol 2013 0.97
29 How to set up an effective national primary angioplasty network: lessons learned from five European countries. EuroIntervention 2009 0.96
30 Time to treatment and three-year mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction-a DANish Trial in Acute Myocardial Infarction-2 (DANAMI-2) substudy. Am J Cardiol 2010 0.94
31 Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009 0.94
32 [ESH/ESC 2007 Guidelines for the management of arterial hypertension]. Rev Esp Cardiol 2007 0.90
33 Platelet aggregation is dependent on platelet count in patients with coronary artery disease. Thromb Res 2011 0.90
34 Pharmacogenetics of the antiplatelet effect of aspirin. Curr Pharm Des 2012 0.84
35 Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2016 0.83
36 Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study. BMC Cardiovasc Disord 2014 0.83
37 Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure. PLoS One 2013 0.82
38 Rapid evaluation of platelet function using the Multiplate® Analyzer. Platelets 2013 0.81
39 Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction. Thromb Haemost 2012 0.81
40 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents. JACC Cardiovasc Interv 2012 0.81
41 Stent for Life Initiative: where are we standing and where are we going? Eur Heart J Acute Cardiovasc Care 2012 0.79
42 Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines. Expert Rev Cardiovasc Ther 2012 0.79
43 [Guidelines for cardiac pacing and cardiac resynchronization therapy]. Rev Port Cardiol 2008 0.78
44 Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction. Platelets 2012 0.78
45 Monitoring aspirin therapy with the Platelet Function Analyzer-100. Scand J Clin Lab Invest 2008 0.77
46 New anticoagulants for atrial fibrillation. J Cardiovasc Med (Hagerstown) 2009 0.76
47 Outcome of unprotected left main percutaneous coronary intervention in surgical low-risk, surgical high-risk, and acute myocardial infarction patients. EuroIntervention 2006 0.76
48 Do the Behring Coagulation Timer and the Platelet Function Analyzer-100 identify the same patients as being aspirin non-responders? Platelets 2007 0.75
49 [Guidelines in cardiac pacing and resynchronization therapy]. Kardiol Pol 2007 0.75
50 [Clopidogrel: background information and use in clinical practice]. Ugeskr Laeger 2003 0.75
51 Aspirin resistance: myth or major problem? Scand J Clin Lab Invest 2008 0.75
52 Dual anti-platelet therapy after coronary drug-eluting stent implantation and surgery-associated major adverse events. Thromb Haemost 2016 0.75
53 Pain and discomfort in closure of femoral access coronary angiography. The CLOSuredEvices Used in everyday Practice (CLOSE-UP) pain sub study. Eur J Cardiovasc Nurs 2013 0.75
54 Establishing primary angioplasty as the preferred treatment for acute myocardial infarction. Scand Cardiovasc J 2002 0.75
55 [Bleeding complications after treatment with antithrombotic agents after acute coronary syndrome]. Ugeskr Laeger 2006 0.75
56 Scintigraphic evaluation of routine filterwire distal protection in percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: a randomized controlled trial. J Nucl Cardiol 2009 0.75
57 CardioPulse Articles. Eur Heart J 2014 0.75
58 Randomized comparison of deliverability and in-hospital complications in implantation of BxSonic(R), Express(R), and Flexmaster(R) coronary stents. EuroIntervention 2005 0.75
59 The German Centre for Cardiovascular Research. Eur Heart J 2012 0.75